AbstractThere is now a robust pipeline of licensed and World Health Organization (WHO)–prequalified typhoid conjugate vaccines with a steady progression of national introductions. However, typhoid fever is responsible for less than half the total global burden ofSalmonelladisease, and even less among children aged <5 years. Invasive nontyphoidalSalmonelladisease is the dominant clinical presentation ofSalmonellain Africa, and over a quarter of enteric fever in Asia is due to paratyphoid A. In this article, we explore the case for combinationSalmonellavaccines, review the current pipeline of these vaccines, and discuss key considerations for their development, including geographies of use, age of administration, and pathways to licensure. While a trivalent typhoid/nontyphoidalSalmonellavaccine is attractive for Africa, and a bivalent enteric fever vaccine for Asia, a quadrivalent vaccine covering the 4 main disease-causing serovars ofSalmonella entericawould provide a single vaccine option for globalSalmonellacoverage.